Clinical Trials

39 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04447716 2025-09-15

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

4 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT02992522 2025-09-09

Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

22 enrolled

LymphoidOther solid neoplasm

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT05279300 2025-08-11

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Phase 1 Recruiting

480 enrolled

Advanced Solid Tumor

NCT04436107 2025-05-23

Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

66 enrolled 52 charts

Lymphoma, Large B-Cell, Diffuse

NCT04578600 2025-04-24

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

8 enrolled

Leukemia, Hairy Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04134936 2024-10-16

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

66 enrolled 21 charts

Lymphoma, Large B-Cell, Diffuse

NCT06547944 2024-08-09

ZGR in TN CLL

30 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05867030 2023-10-17

Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma

Phase 1 Withdrawn

Lymphoma, Follicular

NCT02280525 2023-06-07

Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma

8 enrolled

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04635683 2022-09-30

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Phase 1 Withdrawn

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01886859 2022-09-26

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

27 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, B-Cell

NCT03302728 2022-05-19

EpiBrentlen

6 enrolled

DermatologicLymphoid

Hodgkin Disease, Recurrence, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT01744912 2022-05-11

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

10 enrolled

Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT02954406 2022-02-18

A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma

43 enrolled 27 charts

Lymphoma, Non-Hodgkin

NCT02086604 2022-02-17

Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma

37 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04818372 2021-11-12

Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Phase 1 Unknown

87 enrolled

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT01953692 2021-08-04

MK-3475-013

LymphoidMyeloidPlasma cell

197 enrolled 52 charts

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma, Large B-Cell, Diffuse

NCT01088048 2021-03-18

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

241 enrolled 31 charts

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT01207921 2021-03-10

Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma

28 enrolled

Hodgkin Disease

NCT01542918 2020-08-11

Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

14 enrolled

Lymphoma, Recurrence, Intraocular Lymphoma

NCT01742793 2020-03-04

RID

LymphoidMyeloidOther hematologic neoplasm

12 enrolled

LymphoidPlasma cell

Hodgkin Disease, Multiple Myeloma, Lymphoma, T-Cell

NCT01619761 2020-02-11

NK Cells in Cord Blood Transplantation

Phase 1 Unknown

13 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01732861 2019-12-20

Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma

20 enrolled

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00419250 2019-11-08

A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia

52 enrolled

Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01169298 2019-11-08

A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma

13 enrolled

Leukemia-Lymphoma, Adult T-Cell, Lymphoma, T-Cell, Peripheral

NCT01729104 2019-10-22

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

18 enrolled

Lymphoma, Recurrence, Lymphoma, Mantle-Cell

NCT01429025 2019-10-08

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

26 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT03373305 2019-04-30

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Phase 1 Withdrawn

DermatologicLymphoid

Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT03558750 2019-04-25

Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma

6 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT01056679 2018-03-22

AVD-Rev

30 enrolled

Hodgkin Disease

NCT01766583 2018-03-07

CLEAR

18 enrolled

Lymphoma, B-Cell

NCT01373229 2018-02-05

Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)

21 enrolled 10 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01644799 2018-01-30

Lenalidomide and Idelalisib in Treating Patients With Recurrent Follicular Lymphoma

8 enrolled

Lymphoma, Follicular

NCT01838434 2018-01-30

Lenalidomide With or Without Idelalisib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

106 enrolled

Lymphoma, Mantle-Cell

NCT01400685 2018-01-25

Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL

34 enrolled

Leukemia, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02200848 2018-01-12

Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

5 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00466895 2017-11-14

Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.

37 enrolled

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01254578 2017-09-25

Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers

DermatologicLymphoidOther hematologic neoplasm

17 enrolled

Burkitt Lymphoma, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Leukemia, Promyelocytic, Acute, Leukemia, Myelomonocytic, Acute, Lymphoma, T-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

NCT01750762 2017-04-18

Lenalidomide After Allo Transplant

1 enrolled

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

NCT00543114 2016-05-27

Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL

9 enrolled